Recombinant Human IL-17A, Biotinylated Protein, CF Summary
Product Specifications
Gly24-Ala155
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
BT7955/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and NaCl. |
Reconstitution | Reconstitute at 100 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
Both Biotinylated Recombinant Human IL-17A (Catalog # BT7955/CF) and unlabeled Recombinant Human IL-17A (Catalog # 7955-IL/CF) induces IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 0.12-1.2 ng/mL ng/mL. The similarity in activity highlights that the biotinylated protein is fully functional.
Reconstitution Calculator
Background: IL-17/IL-17A
Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature human IL-17A shares 60% amino acid sequence identity with mouse and rat IL-17A (3, 4). IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells (2). It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F (5, 6). IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD (7, 8). Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F (7). IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection (9-12). It induces chemokine production, neutrophil influx, and the production of antibacterial peptides
(9-11). IL-17A/F likewise induces neutrophil migration, but IL-17F does not (11). IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock (4, 13). In contrast, it can protect against the progression of colitis by limiting chronic inflammation (12). IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity (14, 15).
IL-17A has been shown to exert either tumorigenic or anti-tumor effects (16, 17).
- Gaffen, S.L. (2009) Nat. Rev. Immunol. 9:556.
- Cua, D.J. and C.M. Tato (2010) Nat. Rev. Immunol. 10:479.
- Yao, Z. et al. (1995) J. Immunol. 155:5483.
- Fossiez, F. et al. (1996) J. Exp. Med. 183:2593.
- Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
- Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
- Wright, J.F. et al. (2008) J. Immunol. 181:2799.
- Rong, Z. et al. (2009) Cell Res. 19:208.
- Cho, J.S. et al. (2010) J. Clin. Invest. 120:1762.
- Liang, S.C. et al. (2006) J. Exp. Med. 203:2271.
- Liang, S.C. et al. (2007) J. Immunol. 179:7791.
- O’Connor Jr., W. et al. (2009) Nat. Immunol. 10:603.
- Takahashi, N. et al. (2008) J. Exp. Med. 205:1755.
- Hsu, H. et al. (2008) Nat. Immunol. 9:166.
- Rohn, T.A. et al. (2006) Eur. J. Immunol. 36:2857.
- Wang, L. et al. (2009) J. Exp. Med. 206:1457.
- Kryczek, I. et al. (2009) Blood 114:357.
Citation for Recombinant Human IL-17A, Biotinylated Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site
Authors: ER Goedken, MA Argiriadi, JD Dietrich, AM Petros, N Krishnan, SC Panchal, W Qiu, H Wu, H Zhu, AM Adams, PM Bodelle, L Goguen, PL Richardson, PF Slivka, M Srikumaran, AK Upadhyay, B Wu, RA Judge, A Vasudevan, SM Gopalakris, PB Cox, VS Stoll, C Sun
Scientific Reports, 2022-08-26;12(1):14561.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human IL-17A, Biotinylated Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human IL-17A, Biotinylated Protein, CF and earn rewards!
Have you used Recombinant Human IL-17A, Biotinylated Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image